<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1769">
  <stage>Registered</stage>
  <submitdate>4/12/2007</submitdate>
  <approvaldate>4/12/2007</approvaldate>
  <nctid>NCT00567398</nctid>
  <trial_identification>
    <studytitle>IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients</studytitle>
    <scientifictitle>Multi-center,Prospective, Randomized Trial ToDemonstrate Improved Metabolic Control of PEN VS Dianeal In Diabetic CAPD and APD Patients - The Impendia Trial</scientifictitle>
    <utrn />
    <trialacronym>Impendia</trialacronym>
    <secondaryid>34202</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>ESRD</healthcondition>
    <healthcondition>Diabetes</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Dianeal
Treatment: drugs - Physioneal
Treatment: drugs - Extraneal
Treatment: drugs - Nutrineal

Active Comparator: non glucose sparing - Dianeal only

Experimental: Glucose sparing - Physioneal, Extraneal, Nutrineal


Treatment: drugs: Dianeal
Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)

Treatment: drugs: Physioneal
Physioneal 40 or Physioneal 35

Treatment: drugs: Extraneal
Extraneal - 7.5% Icodextrin

Treatment: drugs: Nutrineal
Nutrineal - 1.1% Amino Acids

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from the baseline value in HbA1c between the PEN group compared to the Dianeal only group</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Glycemic control medication usage, hypoglycemic events, metabolic control, nutritional status, and QOL.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. M/F patients 18 years of age or older

          2. Diagnosis of ESRD (GFR = 15 mL/min)

          3. CAPD or APD using only Dianeal and/or Physioneal, at least 1 exchange of 2.5% or 4.25%
             dextrose/day, no prescribed dry time

          4. DM (Type 1 and 2) on glycemic-control medication, for 90 days

          5. HbA1c &gt; 6.0% but = 12.0%

          6. Blood hemoglobin = 8.0 g/dL, but = 13.0 g/dL</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Cardiovascular event within the last 90 days

          2. Ongoing clinically significant congestive heart failure (NYHA class III or IV)

          3. Allergy to starch-based polymers

          4. Glycogen storage disease

          5. Glycogen storage disease

          6. Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30
             days

          7. Mean Arterial Pressure (MAP) = 125 mm Hg, or volume depleted (MAP &lt; 77) at Screening.

          8. Serum urea &gt; 30 mmol/L

          9. Receiving rosiglitazone maleate</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>43</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Westmead Hospital - Sydney</hospital>
    <hospital>Liverpool Hospital - Sydney</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <hospital>Princess Alexandra Hospital - Wolloongabba</hospital>
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <hospital>Monash Medical Centre - Clayton</hospital>
    <hospital>St. Vincent's Hospital - Fitzroy</hospital>
    <hospital>Gold Coast Hospital - South Port</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2145 - Sydney</postcode>
    <postcode>2170 - Sydney</postcode>
    <postcode>2500 - Wollongong</postcode>
    <postcode>4102 - Wolloongabba</postcode>
    <postcode>5042 - Adelaide</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>4215 - South Port</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Baxter Healthcare Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal)
      in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD)and Automated
      Peritoneal Dialysis (APD) patients leads to improved metabolic control as measured by the
      magnitude of change from the baseline value in the HbA1c levels.

      Secondary Objectives: To demonstrate that use of glucose-sparing PD solutions (PEN vs
      Dianeal) in diabetic (Type 1 and Type 2) CAPD and APD patients leads to lower
      glycemic-control medication requirements, decreased incidence of severe hypoglycemic events
      requiring medical intervention, improved metabolic control, nutritional status, and Quality
      of Life. In a subgroup of patients, the impact of glucose-sparing PD solutions (PEN vs
      Dianeal only) on abdominal fat and left ventricular (LV) structure and function will be
      assessed.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00567398</trialwebsite>
    <publication>Gokal R. Taking peritoneal dialysis beyond the year 2000. Perit Dial Int. 1999;19 Suppl 3:S35-42; discussion S43.
Delarue J, Maingourd C, Couet C, Vidal S, Bagros P, Lamisse F. Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Perit Dial Int. 1998 Sep-Oct;18(5):505-11.
Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int. 2000;20 Suppl 2:S37-41. Review.
Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant. 2006 Feb;21(2):494-8. Epub 2005 Oct 12.
Nundy S, Baron JH. The use of neutral red as a peroperative test of vagal innervation. Scand J Gastroenterol. 1975;10(8):847-50.
Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif. 2005;23(4):303-10. Epub 2005 Jun 23.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Baxter Healthcare Corporation</name>
      <address>Call central contact for information</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>